Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9248 |
High Similarity |
NPD1613 |
Approved |
0.9248 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.9237 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.916 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.9023 |
High Similarity |
NPD3027 |
Phase 3 |
0.8806 |
High Similarity |
NPD4908 |
Phase 1 |
0.8702 |
High Similarity |
NPD1610 |
Phase 2 |
0.8676 |
High Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8593 |
High Similarity |
NPD2861 |
Phase 2 |
0.84 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8344 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8296 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8258 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8255 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8224 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8201 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.8143 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.8058 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8015 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7987 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7987 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7987 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7902 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7899 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7899 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7898 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7895 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7885 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7867 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7863 |
Intermediate Similarity |
NPD228 |
Approved |
0.7848 |
Intermediate Similarity |
NPD5494 |
Approved |
0.784 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7838 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7838 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7826 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7799 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7791 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7763 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7758 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.773 |
Intermediate Similarity |
NPD7054 |
Approved |
0.771 |
Intermediate Similarity |
NPD3022 |
Approved |
0.771 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7707 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7702 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7692 |
Intermediate Similarity |
NPD37 |
Approved |
0.7683 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7669 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7669 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7658 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7658 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7658 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7655 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7655 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7655 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7651 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7643 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7643 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7639 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7635 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7635 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7626 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7616 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7606 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7589 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7584 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7568 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7564 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7564 |
Intermediate Similarity |
NPD4678 |
Approved |
0.753 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7518 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7516 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD7157 |
Approved |
0.75 |
Intermediate Similarity |
NPD4536 |
Approved |
0.75 |
Intermediate Similarity |
NPD4538 |
Approved |
0.75 |
Intermediate Similarity |
NPD3705 |
Approved |
0.75 |
Intermediate Similarity |
NPD2684 |
Approved |
0.75 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7483 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7483 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7483 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD968 |
Approved |
0.7468 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7467 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7467 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7467 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7467 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7456 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7456 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7452 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.744 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7434 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7434 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7425 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7417 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7407 |
Intermediate Similarity |
NPD7843 |
Approved |
0.74 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7394 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7391 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7391 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7375 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7361 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7355 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7343 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7338 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7333 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7333 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7329 |
Intermediate Similarity |
NPD7095 |
Approved |
0.732 |
Intermediate Similarity |
NPD3750 |
Approved |
0.732 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.732 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7313 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7312 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7312 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7305 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7296 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7293 |
Intermediate Similarity |
NPD290 |
Approved |
0.7279 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7278 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7267 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7267 |
Intermediate Similarity |
NPD4663 |
Approved |
0.7248 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7244 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7244 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7237 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7237 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7237 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7234 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7234 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7229 |
Intermediate Similarity |
NPD27 |
Approved |
0.7229 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7226 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7225 |
Intermediate Similarity |
NPD7906 |
Approved |
0.7219 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7212 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7209 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7208 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7208 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD5929 |
Approved |
0.7197 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7194 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7193 |
Intermediate Similarity |
NPD7311 |
Approved |
0.7193 |
Intermediate Similarity |
NPD7310 |
Approved |
0.7193 |
Intermediate Similarity |
NPD7312 |
Approved |
0.7193 |
Intermediate Similarity |
NPD4577 |
Approved |
0.7193 |
Intermediate Similarity |
NPD7313 |
Approved |
0.7193 |
Intermediate Similarity |
NPD4578 |
Approved |
0.7181 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7179 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7179 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7179 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7176 |
Intermediate Similarity |
NPD940 |
Approved |
0.7176 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7176 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7176 |
Intermediate Similarity |
NPD846 |
Approved |
0.7172 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7171 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7171 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7169 |
Intermediate Similarity |
NPD2970 |
Approved |
0.7169 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7161 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7153 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7153 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7152 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7151 |
Intermediate Similarity |
NPD7309 |
Approved |
0.7143 |
Intermediate Similarity |
NPD3384 |
Approved |
0.7143 |
Intermediate Similarity |
NPD3382 |
Approved |
0.7143 |
Intermediate Similarity |
NPD3383 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7133 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7125 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7117 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7108 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7108 |
Intermediate Similarity |
NPD3051 |
Approved |
0.7101 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7101 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7101 |
Intermediate Similarity |
NPD8156 |
Discontinued |
0.7099 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7097 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7089 |
Intermediate Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7081
|
Intermediate Similarity |
NPD6072 |
Discontinued |